Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy
- PMID: 22505891
- PMCID: PMC3312212
- DOI: 10.1155/2012/625434
Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy
Abstract
Hypogonadism in older men is a syndrome characterized by low serum testosterone levels and clinical symptoms often seen in hypogonadal men of younger age. These symptoms include decreased libido, erectile dysfunction, decreased vitality, decreased muscle mass, increased adiposity, depressed mood, osteopenia, and osteoporosis. Hypogonadism is a common disorder in aging men with a significant percentage of men over 60 years of age having serum testosterone levels below the lower limits of young male adults. There are a variety of testosterone formulations available for treatment of hypogonadism. Data from many small studies indicate that testosterone therapy offers several potential benefits to older hypogonadal men. A large multicenter NIH supported double blind, placebo controlled study is ongoing, and this study should greatly enhance the information available on efficacy and side effects of treatment. While safety data is available across many age groups, there are still unresolved concerns associated with testosterone therapy. We have reviewed the diagnostic methods as well as benefits and risks of testosterone replacement therapy for hypogonadism in aging men.
Figures
Similar articles
-
New Biomarkers to Evaluate Hyperandrogenemic Women and Hypogonadal Men.Adv Clin Chem. 2018;86:71-125. doi: 10.1016/bs.acc.2018.06.001. Epub 2018 Aug 18. Adv Clin Chem. 2018. PMID: 30144842 Review.
-
Testosterone supplementation therapy for older men: potential benefits and risks.J Am Geriatr Soc. 2003 Jan;51(1):101-15; discussion 115. doi: 10.1034/j.1601-5215.2002.51018.x. J Am Geriatr Soc. 2003. PMID: 12534854 Review.
-
A practical guide to male hypogonadism in the primary care setting.Int J Clin Pract. 2010 May;64(6):682-96. doi: 10.1111/j.1742-1241.2010.02355.x. Int J Clin Pract. 2010. PMID: 20518947 Free PMC article. Review.
-
A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms.Arch Gen Psychiatry. 2000 Feb;57(2):141-7; discussion 155-6. doi: 10.1001/archpsyc.57.2.141. Arch Gen Psychiatry. 2000. PMID: 10665616 Clinical Trial.
-
Demographic and Clinical Correlates of Patient-Reported Improvement in Sex Drive, Erectile Function, and Energy With Testosterone Solution 2.J Sex Med. 2016 Aug;13(8):1212-9. doi: 10.1016/j.jsxm.2016.05.010. Epub 2016 Jun 18. J Sex Med. 2016. PMID: 27329542 Clinical Trial.
Cited by
-
Aging and declining testosterone: past, present, and hopes for the future.J Androl. 2012 Nov-Dec;33(6):1111-8. doi: 10.2164/jandrol.112.017160. Epub 2012 Aug 9. J Androl. 2012. PMID: 22879528 Free PMC article. Review.
-
Age-Related Male Hypogonadism and Cognitive Impairment in the Elderly: Focus on the Effects of Testosterone Replacement Therapy on Cognition.Geriatrics (Basel). 2020 Oct 16;5(4):76. doi: 10.3390/geriatrics5040076. Geriatrics (Basel). 2020. PMID: 33081371 Free PMC article. Review.
-
Elevated Dihydrotestosterone is Associated with Testosterone Induced Erythrocytosis.J Urol. 2015 Jul;194(1):160-5. doi: 10.1016/j.juro.2015.01.038. Epub 2015 Jan 14. J Urol. 2015. PMID: 25596360 Free PMC article.
-
BMI1 promotes steroidogenesis through maintaining redox homeostasis in mouse MLTC-1 and primary Leydig cells.Cell Cycle. 2020 Aug;19(15):1884-1898. doi: 10.1080/15384101.2020.1779471. Epub 2020 Jun 28. Cell Cycle. 2020. PMID: 32594840 Free PMC article.
-
Sex differences in anxiety and depression: role of testosterone.Front Neuroendocrinol. 2014 Jan;35(1):42-57. doi: 10.1016/j.yfrne.2013.09.001. Epub 2013 Sep 24. Front Neuroendocrinol. 2014. PMID: 24076484 Free PMC article. Review.
References
-
- Gooren LJ. Late-onset hypogonadism. Frontiers of Hormone Research. 2009;37:62–73. - PubMed
-
- Morales A, Tenover JL. Androgen deficiency in the aging male: when, who, and how to investigate and treat. Urologic Clinics of North America. 2002;29(4):975–982. - PubMed
-
- Frajese GV, de Martino MU, Calcagni E, et al. The epidemiology of partialandrogen deficiency in aging men (PADAM) Journal of Endocrinological Investigation. 2005;28(3):3–7. - PubMed
-
- Morales A, Schulman CC, Tostain J, Wu FCW. Testosterone Deficiency Syndrome (TDS) needs to be named appropriately—the importance of accurate terminology. European Urology. 2006;50(3):407–409. - PubMed
-
- Matsumoto AM. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. The Journals of Gerontology A . 2002;57(2):M76–M99. - PubMed
LinkOut - more resources
Full Text Sources